ArticlebioRxiv : the preprint server for biology2025
ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.
Randolph M Johnson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.